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Limited prevalence data for HIV, hepatitis B surface an-
tigen (HBsAg), and hepatitis C virus (HCV) exist for Afghan-
istan. We studied a cross-sectional sample of adult injection 
drug users (IDUs) in Kabul, Afghanistan, from June 2005 
through June 2006. Study participants completed interview-
er-administered questionnaires and underwent testing for 
HIV, antibody to HCV, and HBsAg. Overall prevalences of 
HIV, HCV, and HBsAg were 3.0% (95% confi dence interval 
[CI] 1.7%–5.1%), 36.6% (95% CI 32.2%–41.0%), and 6.5% 
(95% CI 4.2%–8.7%), respectively (N = 464). Among male 
IDUs (n = 463), risky behavior, including sharing syringes 
(50.4%), paying women for sex (76.2%), and having sex 
with men or boys (28.3%), were common. Needle sharing, 
injecting for >3 years, and receiving injections from nonmedi-
cal providers were independently associated with increased 
risk for HCV infection. The high prevalence of risky behavior 
indicate that Kabul is at risk for an HIV epidemic. Scale-up 
of harm-reducing interventions is urgently needed.
Injection drug use has become increasingly common in Central and South Asia, fostered by readily available 
opium and heroin (1,2). Many countries in this region are 
experiencing HIV epidemics driven by injection drug use 
that is extending to other populations (3,4). Four countries 
bordering Afghanistan (Pakistan, Tajikistan, Uzbekistan, 
and Iran), which provided refuge to many Afghans during 
the extended period of civil war, are experiencing HIV epi-
demics among injection drug users (IDUs) (1,3,5,6). The 
population of Kabul, the capital of Afghanistan, has in-
creased to ≈3 million since 2001 because of returning refu-
gees (7,8). Refugees may have acquired high-risk bebavior, 
such as injection drug use, that may place communities at 
risk upon their return.
Afghanistan provided 88% of the world’s opium 
supply in 2005 (9). Although noninjection use of opium 
(smoking, vaporization, or oral ingestion) is traditional in 
Afghanistan, injecting likely represents a new behavior 
(10). This behavior may be learned in countries of refuge 
during times of political unrest, as indicated by the partici-
pants in a United Nations Offi ce on Drugs and Crime study 
in 2003, in which 50% (n = 34) of participants had started 
using heroin in either Pakistan or Iran (11). A prior study 
in the border city of Quetta, Pakistan, reported that Afghan 
IDUs were more likely than their Pakistani counterparts to 
engage in risky behavior (12). These observations raised 
concern that injection drug use and accompanying high-
risk behavior are increasing in Afghanistan and that a con-
centrated HIV epidemic may soon ensue (13).
There were an estimated 470 IDUs in Kabul in 2003, 
although the United Nations Offi ce on Drugs and Crime 
Afghanistan survey in 2005 estimated that there were 
50,000 heroin users in Afghanistan, of whom 14% reported 
injecting drugs (10,11). The same study also estimated that 
most IDUs reside in Kabul and, of all heroin-using IDUs 
interviewed, 70% stated they had shared needles (10). Of 
IDUs interviewed, all were men, but anecdotal evidence 
from harm-reduction programs indicated that a few IDUs 
in Kabul were female (10). Although drug use is illegal in 
Afghanistan and warrants either rehabilitation for a fi rst 
offense or imprisonment for recurrent offenses (14) the 
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motivating factor stated for initiating injection was con-
stant pain that was not relieved by smoking (10). However, 
little is currently known about other aspects of injection 
drug use in Kabul, such as syringe sources or harm-reduc-
ing programs.
Little data are available on HIV, hepatitis B surface 
antigen (HBsAg), or hepatitis C virus (HCV) prevalence 
and associated risk behavior in Afghanistan. As of October, 
2005, only 41 cases of HIV had been reported, although 
this is believed to underestimate the potential problem (15). 
We assessed prevalence of HIV, HCV, HBsAg, and associ-
ated risk behavior among IDUs in Kabul.
Methods
Study Design and Participants
We conducted a cross-sectional study of IDUs in 
Kabul, Afghanistan, from June 2005 through June 2006, 
through the Voluntary Counseling and Testing (VCT) Cen-
ter at the Central Polyclinic, an Afghan Ministry of Pub-
lic Health facility. At the time of this study, there were 3 
harm-reduction programs in Kabul, of which 1 had on-site 
syringe exchange.
Eligible participants were those >18 years of age who 
reported having injected drugs within the past 6 months 
(confi rmed through injection marks) and were able to pro-
vide informed consent. Before data collection, this study 
was reviewed and approved by the investigational review 
boards of the University of California, San Diego; the US 
Naval Medical Research Unit No. 3; the Walter Reed Army 
Institute of Research; and the Ministry of Public Health of 
Afghanistan.
Procedures
Potential participants were approached by an expe-
rienced outreach worker known to them. If participants 
were interested in entering the study, they accompanied the 
outreach worker to the VCT Center. At the VCT, a study 
representative explained the study in a confi dential setting 
and obtained informed consent. The participant was as-
signed a unique study number, the sole identifi er, which 
was required for receiving test results as needed. Partici-
pants were interviewed by a trained study representative 
matched to the participant’s sex. The questionnaire includ-
ed sociodemographics, travel and medical histories, past 
and current drug use and sexual behavior, and knowledge 
of bloodborne and sexually transmitted infections. No data 
were recorded from those declining participation or ineli-
gible to enter the study.
Pretest and posttest counseling were given, and rapid 
antibody testing was performed by using the Abbott De-
termine HIV 1/2 test, the Abbott Determine HBsAg test 
(both from Abbott Diagnostics Japan, Tokyo, Japan), and 
the Standard Diagnostics HCV test (Standard Diagnostics 
Laboratories, Yongin-si Gyeonggi-do, Republic of Korea) 
for HCV. Participants with a positive HIV test result un-
derwent sequential testing with the OraSure OraQuick HIV 
1/2 test (OraSure Technologies, Bethlehem, PA, USA). 
Repeatedly positive rapid HIV test results were confi rmed 
by Western blot (HIV BLOT 2.2; GeneLabs Diagnostics, 
Singapore). Hepatitis B was confi rmed with a second, se-
rum-based rapid test (Standard Diagnostics HBV; Standard 
Diagnostics Laboratories) because nucleic acid testing was 
not available in Kabul. The Abbott and Standard Diag-
nostics HBsAg rapid tests had sensitivities of 99.0% and 
99.0% and specifi cities of 99.0% and 100.0%, respectively, 
and a positive predictive value of 99.9%, assuming a base-
line HBsAg prevalence of 5.0% (16,17). The presence of 
antibody to HCV was confi rmed with a recombinant immu-
noblot assay (RIBA) test (RIBA 3.0 SIA; Chiron Corpora-
tion, Emeryville, CA, USA). 
All confi rmatory testing was performed at the VCT 
Center in Kabul by trained laboratory personnel. All par-
ticipants received a small nonmonetary gift and risk-reduc-
tion counseling, with referrals for detoxifi cation and needle 
and syringe programs upon request.
Statistical Analysis
Prevalence of infection was calculated with confi -
dence intervals (CIs) based on Poisson distribution for 
HIV and binomial distribution for HBsAg and HCV. The 
only female participant was excluded from remaining 
analyses. Correlates of HIV, HBsAg, and HCV infection 
were assessed with univariate and multivariate logistic 
regression analyses. Variables were entered into a mul-
tivariate model if they were signifi cantly associated with 
HIV, HBsAg, or HCV infection at the 5% level in uni-
variate analysis or showed epidemiologic relationships. A 
multivariate model was generated to identify factors inde-
pendently associated with HIV, HBsAg, and HCV infec-
tions by using the likelihood ratio test to determine which 
variables were retained.
Results
Sociodemographic Data and Prevalence of Infection
A total of 464 participants were enrolled; 463 were 
male. Fourteen participants (3.0%, 95% CI 1.7%–5.1%) 
were infected with HIV, 30 (6.5%, 95% CI 4.2%–8.7%) 
were positive for HBsAg, 170 (36.6%, 95% CI 32.2%–
41.0%) were infected with HCV, and 7 (1.5%, 95% CI 
0.6%–3.1%) were coinfected with HIV and HCV.
Among male participants, most were Afghan, had 
traveled outside Afghanistan in the previous 10 years, and 
reported heroin as their most frequently used drug in the 
past 6 months, either alone (42.4%) or with pheniramine 
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maleate (56.0%) (online Appendix Table, available from 
www.cdc.gov/EID/content/13/9/1327-appT.htm).
Risk Behavior
High-risk injection and sexual behavior were common. 
Sharing needles or syringes (50.4%) and diffi culty obtain-
ing new syringes (43.6%) were frequently reported. Patron-
izing female sex workers and having sexual relations with 
men or boys were also common. More than half the partici-
pants had been incarcerated; of these, nearly one third in-
jected drugs while in prison. A total of 23.1% had received 
a therapeutic injection in the past 6 months, and 5.2% had 
sold or donated blood (online Appendix Table).
Correlates of HIV, HBsAg, and HCV Infection
No sociodemographic variables were signifi cantly as-
sociated with HIV or HBsAg infection. Sharing needles and 
injecting drugs while in prison were associated with HBsAg 
by univariate logistic regression analysis (online Appendix 
Table). Multivariate analysis showed that HBsAg remained 
associated with injecting drugs in prison (adjusted odds ra-
tio 3.23, 95% CI 1.16–9.00). Univariate analysis showed 
that those with HIV infections were more likely to report 
needle or syringe sharing and injecting drugs for >3 years 
(online Appendix Table). No variables were independently 
associated with HIV infection by multivariate logistic re-
gression analysis (results not shown).
Participants with HCV infection were less likely to be 
educated or married and had higher incomes (online Ap-
pendix Table). HCV infection was associated with needle 
or syringe sharing, injecting drugs for >3 years, having sex 
with men or boys, and receiving injections from a non-
medical provider (online Appendix Table). Adjustment 
by demographic factors did not appreciably change these 
relationships. Multivariate logistic regression showed that 
needle or syringe sharing, injecting drugs for >3 years, and 
receiving injections from a nonmedical provider were in-
dependently associated with HCV infection, and inverse 
associations persisted for higher education level and for 
being married (Table).
Discussion
This report is among the fi rst to describe HIV, HBsAg, 
and HCV prevalence and risk behavior in Afghanistan. The 
low HIV prevalence among IDUs in Kabul is not surprising 
given the short median duration of injection drug use. Al-
though opium has been used for centuries in Afghanistan, 
our data are consistent with the suggestion that injection 
drug use is a relatively new behavior in this setting (10). 
Although HIV prevalence was low, 37% were HCV infect-
ed, a fi nding that potentially foreshadows an HIV epidemic 
caused by risk factors shared by these infections.
Injecting drugs in prison was related to HBsAg and 
marginally to HIV by univariate analysis, which are simi-
lar to fi ndings in Iran and other settings (3,18,19). In Iran, 
Zamani et al. reported that that multiple incarcerations in-
creased likelihood of HIV infection (20). We did not ob-
serve this relationship, but this result may be due to low 
statistical power. However, 47% of the Iranian prison popu-
lation is incarcerated because of drug-related offenses (18). 
Afghan law allows an addict, as diagnosed by a medical 
professional, to enter a detoxifi cation facility, which may 
reduce the number and exposure of IDUs to prison settings. 
Because one third of Afghan IDUs who had been incar-
cerated reported drug injection in prisons, prisons should 
remain a priority site for needle and syringe programs.
The established risk factors of needle sharing and dura-
tion of injection use were strongly related to both HIV and 
HCV infections. The prevalence of HBsAg was relatively 
low among the IDUs and close to that reported by Inter-
national Committee of the Red Cross/Crescent–supported 
blood banks in 2004. While only those with acute or active 
hepatitis B would have circulating antigen, the prevalence 
of hepatitis B in this group still seems comparatively low, 
given the prevalence of risky behavior. The prevalence of 
HIV and hepatitis B infection may not have not reached 
suffi cient levels to result in a self-sustaining epidemic; 
further surveillance is warranted. The prevalence of 
HBsAg likely underestimates the number of IDUs exposed 
to hepatitis B. Because hepatitis B infection resolves after 
the acute phase in 90%–95% of those infected as adults, 
the actual proportion of IDUs infected may approach or 
exceed 64.7% of participants (21). A more reliable number 
might be accessed through testing for antibody to HbsAg, 
which might be used to create a cost-effective vaccination 
program for this high-risk group.
Although donating blood was not associated with any 
of the 3 infections, risk for bloodborne infection through 
iatrogenic routes deserves emphasis because 8.3% of 
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Table. Factors independently associated with HCV infection  
(n = 170) by multivariable analysis in 463 male injection drug 
users, Kabul, Afghanistan* 
Factor Value
HCV prevalence 107 (36.8) 
Demographic factors 
 Married 0.60 (0.40–0.92) 
 Higher educational level 0.51 (0.29–0.88) 
Drug practices 
 Ever shared needle or  syringe 2.60 (1.71–3.96) 
 Duration injection drug use >3 y 3.28 (2.17–4.96) 
Medical encounters 
 Injections by a nonmedical provider 2.71 (1.26–5.82) 
*HCV, hepatitis C virus. Values are no. (%) or adjusted odds ratio (95% 
confidence interval). Analysis was adjusted for marital status, educational 
level, duration of injecting, sharing needles or syringes, and injections by a 
nonmedical provider. 
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participants who reported donating or selling blood were 
infected with HIV. A prior report estimated that only 30% 
of blood donations were screened in Afghanistan (22). Fur-
thermore, those infected with HCV were more likely to 
have had injections from nonmedical providers, which has 
been linked to a high prevalence of HCV and hepatitis B in 
neighboring Pakistan (23).
Our study has some limitations. Respondent-driven 
sampling was not possible because of concerns of compro-
mising the identities of IDUs; participants were enrolled 
by convenience sampling, which may not be representative 
of IDUs in Kabul. Because risky behavior was assessed by 
self-reporting, socially desirable responses may have been 
made. Analysis of factors associated with HIV and HBsAg 
had low power because of low prevalence of these infec-
tions, which potentially masks some associations. Addi-
tionally, testing for surface antigen may have underestimat-
ed the true prevalence of hepatitis B infection because only 
those with acute or chronic infections would be detected. 
Another approach for future studies would be screening for 
both surface antigen and antibody to HbsAg and offering 
vaccination to IDUs negative for this antibody.
In summary, although prevalence of HIV and HBsAg 
is low among IDUs in Kabul, the prevalence of HCV and 
high-risk behavior are alarmingly high. Political instabil-
ity, poverty, mobility, and low literacy may also increase 
vulnerability of IDUs to HIV and other bloodborne or sexu-
ally transmitted infections (13). During the study, 1 needle 
and syringe program and 3 drug rehabilitation and coun-
seling programs were operating in Kabul; opioid substitu-
tion treatment was not available. Initiation or scale-up of 
interventions, particularly needle and syringe programs and 
opioid substitution therapy, are urgently needed to prevent 
an HIV epidemic among Afghan IDUs. Attempts to pre-
vent or control HIV and other bloodborne infections among 
IDUs without adequate coverage of IDUs by harm-reduc-
tion programs have been unsuccessful (24,25). However, 
settings with outreach programs that linked VCT, needle 
and syringe programs, and opiate substitution therapies 
have stabilized HIV prevalence among IDUs at low lev-
els (25,26). Political support for harm-reduction and HIV 
awareness campaigns among the Ministries of Counter 
Narcotics, Public Health, and Religious Affairs is present 
in Afghanistan; donor attention is urgently needed to ex-
pand these efforts to avert an HIV epidemic.
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